Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.41 -3.4%	$1.38	$1.01 ▼ $3.45	$413.60M	1.05	1.61 million shs	418,603 shs
HLVX HilleVax	$2.13 -1.8%	$1.95	$1.34 ▼ $2.17	$108.81M	0.76	303,487 shs	52,064 shs
PRME Prime Medicine	$4.29 -10.6%	$2.08	$1.11 ▼ $6.75	$576.98M	2.33	1.73 million shs	4.41 million shs
RZLT Rezolute	$5.11 -3.9%	$4.26	$2.22 ▼ $6.19	$454.96M	1.03	664,939 shs	717,567 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-3.42%	-3.42%	-4.73%	+20.51%	-54.22%
HLVX HilleVax	-1.84%	+3.90%	+15.14%	+29.09%	+21.71%
PRME Prime Medicine	-10.63%	+4.63%	+193.84%	+245.97%	-25.78%
RZLT Rezolute	-3.95%	+2.82%	+21.67%	+93.56%	+5.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	3.0878 of 5 stars	3.5	2.0	2.8	2.5	1.3
HLVX HilleVax	2.087 of 5 stars	1.0	5.0	3.0	3.3	1.3
PRME Prime Medicine	3.7295 of 5 stars	4.4	1.0	2.7	5.0	0.6
RZLT Rezolute	2.5473 of 5 stars	3.6	1.0	2.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.57	224.21% Upside
HLVX HilleVax	2.00	Hold	$2.00	-6.10% Downside
PRME Prime Medicine	2.75	Moderate Buy	$10.08	135.04% Upside
RZLT Rezolute	3.14	Buy	$11.83	131.57% Upside

Current Analyst Ratings Breakdown

Latest HLVX, RZLT, PRME, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
PRME Prime Medicine	$3.85M	150.02	N/A	N/A	$1.37 per share	3.13
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$2.15	N/A	N/A	N/A	N/A	-51.86%	-41.45%	8/14/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest HLVX, RZLT, PRME, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/8/2025	Q1 2025	HLVX HilleVax	-$0.37	-$0.12	+$0.25	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	33.71%	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	12.35	12.35
HLVX HilleVax	N/A	25.32	25.32
PRME Prime Medicine	N/A	6.50	6.50
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
HLVX HilleVax	86.42%
PRME Prime Medicine	70.37%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
HLVX HilleVax	24.90%
PRME Prime Medicine	22.93%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.29 million	242.49 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
PRME Prime Medicine	234	134.49 million	100.38 million	Optionable
RZLT Rezolute	40	85.52 million	69.79 million	Optionable

HLVX, RZLT, PRME, and ERAS Headlines

Recent News About These Companies

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $11.83

July 12, 2025 | americanbankingnews.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...

July 10, 2025 | finance.yahoo.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 9, 2025 | globenewswire.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from Analysts

July 9, 2025 | marketbeat.com

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27, 2025 | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of Stock

June 26, 2025 | marketbeat.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in Stock

June 24, 2025 | marketbeat.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Young-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 23, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025 | globenewswire.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 21, 2025 | finanznachrichten.de

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

May 20, 2025 | finance.yahoo.com

Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment

May 15, 2025 | nasdaq.com

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

FDA grants breakthrough status to Rezolute’s hypoglycemia therapy

May 6, 2025 | investing.com

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025 | globenewswire.com

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025 | seekingalpha.com

Rezolute Closes $96.9 Million Underwritten Offering

April 28, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, RZLT, PRME, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$1.41 -0.05 (-3.42%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+2.13%)

As of 07/15/2025 06:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

HilleVax NASDAQ:HLVX

$2.13 -0.04 (-1.84%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.01 (-0.70%)

As of 07/15/2025 07:26 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Prime Medicine NYSE:PRME

$4.29 -0.51 (-10.63%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$4.22 -0.07 (-1.52%)

As of 07/15/2025 07:57 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Rezolute NASDAQ:RZLT

$5.11 -0.21 (-3.95%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.16 +0.05 (+0.98%)

As of 07/15/2025 06:59 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time